Cardiovascular Revascularization Medicine
Volume 7, Issue 4 , Pages 237-239 , October 2006

An audit of the use and complications of glycoprotein IIb/IIIa inhibitors in percutaneous coronary intervention against national UK standards

Received 20 May 2006 ,Revised 18 July 2006 ,Accepted 18 July 2006.

References 

  1. Chesebro JH, Fuster V. Thrombosis in unstable angina. N Engl J Med. 1992;327:192–194
  2. The EPIC Investigators . Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasties. N Engl J Med. 1994;330:956–961
  3. The IMPACTII Investigators . Randomized placebo-controlled trial of effect of eptifibatide on complications of percutaneous coronary intervention: IMPACT-II. Lancet. 1997;349:1422–1428
  4. The CAPTURE Investigators . Randomized placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: the CAPTURE study. Lancet. 1997;349:1429–1435[Erratum, Lancet 350 (1997) 744]
  5. The EPILOG Investigators . Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. N Engl J Med. 1997;336:1689–1696
  6. The RESTORE Study Group . Effects of platelet glycoprotein IIb/IIIa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty. Circulation. 1997;96:1445–1453
  7. Alexander JH, Alexander K, Kong DF, Tung CY, Whellan D. Session high-lights from American heart association scientific sessions: November 9–12, 1997. Am Heart J. 1998;135:157–180
  8. Phillips DR, Charo IF, Parise LV, Fitzgerald LA. The Platelet membrane glycoprotein IIb-IIIa complex. Blood. 1988;71:831–843
  9. Lefkovits J, Plow EF, Topol EJ. Platelet glycoprotein IIb/IIIa receptors in cardiovascular medicine. N Engl J Med. 1995;332:1553–1559
  10. Collar BS. Blockade of platelet GP IIb/IIIa receptors as an antithrombotic strategy. Circulation. 1995;92:2373–2380
  11. Lincoff AM, Califf RM, Anderson KM, et al. Evidence for prevention of death and myocardial infarction with platelet membrane glycoprotein IIb/IIIa receptor blockade by abciximab(c7E3 Fab) among patients with unstable angina undergoing percutaneous coronary revascularization. J Am Coll Cardiol. 1997;30:149–156
  12. Klootwijk P, Meiji S, Melkert R, Simoons ML. Reduction of recurrent ischaemia with abciximab during continuous ECG-ischaemia monitoring in patients with unstable angina refractory to standard treatment(CAPTURE). J Am Coll Cardiol. 1997;29(Suppl A):367A;[Abstract]
  13. Topol EJ, Ferguson JJ, Weisman HF, et al. Long-term protection from myocardial ischaemic events in a randomized trial of brief integrin (β, blockade with percutaneous coronary intervention. JAMA. 1997;278:479–484
  14. NICE Technology Appraisal Guidance—No: 47; September 2002.
  15. The EPISTENT Investigators . Randomized placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein IIb/IIIa blockade. The EPISTENT Investigators. Evaluation of Platelet IIb/IIIa Inhibitor for Stenting. Lancet. 1998;352:87–92

PII: S1553-8389(06)00186-2

doi: 10.1016/j.carrev.2006.07.005

Cardiovascular Revascularization Medicine
Volume 7, Issue 4 , Pages 237-239 , October 2006

Article Tools

* Image Usage & Resolution